Navigation Links
Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
Date:5/15/2013

abine/cisplatin.5

"These data from the LUX-Lung 6 trial add to the growing body of knowledge for the investigational compound, afatinib, in EGFR mutation-positive advanced non-small cell lung cancer," said William Goeckeler , PhD, director, Oncology Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "This is the second Phase III trial involving afatinib in this patient population to meet its primary efficacy endpoint and to incorporate health-related quality of life measures into the study design."

The LUME-Lung 2 Clinical Trial of Nintedanib
LUME-LUNG 2 (Efficacy) Abstract: #8034
Poster Discussion:  Sunday, June 2, 11:30 AM-12:30 PM, poster board #23

This randomized, double-blinded Phase III study evaluated nintedanib plus pemetrexed compared to pemetrexed plus placebo in patients with advanced non-squamous NSCLC not responding to, or who progressed after, first-line chemotherapy.2 LUME-Lung 2 was halted at the recommendation of the Independent Data Monitoring Committee after 713 patients had been enrolled. This decision was based on the results of an interim review of efficacy (PFS) for a pre-defined futility analysis, and was not safety related. At the point of the interim review, PFS did not appear significantly improved compared to the comparator arm.

Data will be presented on the 713 patients who enrolled; results showed that the addition of nintedanib to pemetrexed improved PFS (HR=0.83, p=0.04) even though enrollment was stopped prematurely.2 Patients treated with nintedanib plus pemetrexed (n=353) lived for a median of 4.4 months before their tumor started to grow again (PFS), compared to 3.6 months for patients assigned to the pemetrexed plus placebo arm (n=360).2

A higher incidence of greater than or equal to grade 3 elevated ALT (23% versus 7%) and AST (12% versus 2%)2
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE MKT: ... biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... the Company achieved the Public Notice (Gong Shi) ... of TPI,s Qionglai Facility (QLF) from the China ... period is a significant procedure of GMP certification ...
(Date:12/22/2014)... NxStage Medical, Inc. (NASDAQ: NXTM ... announced today that the U.S. Food and Drug ... perform hemodialysis overnight while the patient is at ... System One is the first and only hemodialysis ... Home nocturnal hemodialysis is an ...
(Date:12/22/2014)... 2014  ConvaTec, a privately-held medical products and technologies ... Interim Chief Executive Officer of the company, effective December ... Berger .  "The Board of Directors of ConvaTec thanks ... the past three years," said Magnus Lundberg , ... confident that the company is well positioned for the ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
(Date:12/26/2014)... CA (PRWEB) December 26, 2014 ... score of 3.1 out of 5. This score reflects ... low level of product specialization, low switching costs and ... is reduced by the low availability of substitutes for ... world price of steel and aluminum, key inputs in ...
(Date:12/26/2014)... The Biofeedback Federation of Europe annual ... in Rome, Italy and is hosted by the Salesian ... on a wide variety of topics such as ADHD, ... training in athletes. The scientific program will feature the ... monitoring allows clients to see what is going on ...
(Date:12/26/2014)... 26, 2014 “Many people become overwhelmed ... injury claim issues and phone calls with insurance companies,” ... article featuring their free eBook on pedestrian and ... on pedestrian and bicycle auto accident claims assures the ... capable of professionally handling their case while they focus ...
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on the Best ... 2014. The awards program, created in 2000, is one ... the country. The program is a public/private partnership between ... Economic Development, the Pennsylvania State Council of the Society ... Journal. , Charlie Wilson, Vice President of ...
(Date:12/26/2014)... Parker & Sons, Inc. a reliable ... cooling and plumbing contractor services throughout Arizona announces ... 2014 with regard to air-conditioning systems. Residential and ... for its incredibly hot summers. Working with an ... details of a wide variety of systems made ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3
... Physicians Rank Increased Bystander CPR, Faster Patient-to-Doctor ... Areas in,Resuscitation, WASHINGTON, Nov. 7 ... by the American College of Emergency Physicians ... the emergency physicians surveyed,believe that resuscitation practices ...
... use grant to advance,resuscitation research, NEW ORLEANS, ... PHI) today announced that Dr. Ohad Ziv, Clinical ... as the,recipient of the second annual American Heart ... from Philips Healthcare, the Fellowship encourages,young investigators in ...
... with mangosteen BioActiveX3 Complex(TM) features toxin-free ingredients, green chemistry technology ... ... formulas, SALT LAKE CITY, Nov. 7 Global nutrition leader ... its sixth international convention in Salt Lake City. This personal care,brand ...
... Andy Tate, a financial advisor with,Minneapolis-based North Star Resource ... Financial Advisors for Doctors" in 2008. The list of,top ... and is based on,nominations from clients and survey data ... received this recognition," said Dave,Vasos, co-president and chief financial ...
... Highlighted by Submission of NDA for Novel Antidepressant and ... Steady Global Growth for Once-Daily Tramadol - ... DDSS) today reported its results for the third quarter ended,September ... "We are very pleased with the progress of our ...
... increase by 37% over same quarter in Fiscal ... dollars unless otherwise noted) BELLEVILLE, ON, Nov. ... a research-based, technology-driven Canadian,biopharmaceutical company, today announced financial ... year, ending September 30, 2008., "Our revenues ...
Cached Medicine News:Health News:Emergency Physicians Reveal Strategies for Improving Sudden Cardiac Arrest Survival Rates in the U.S. 2Health News:Emergency Physicians Reveal Strategies for Improving Sudden Cardiac Arrest Survival Rates in the U.S. 3Health News:Philips Announces 2008 Winner of American Heart Association-Philips Resuscitation Fellowship Award 2Health News:Philips Announces 2008 Winner of American Heart Association-Philips Resuscitation Fellowship Award 3Health News:XanGo Introduces Glimpse(TM) Intuitive Skin Care 2Health News:XanGo Introduces Glimpse(TM) Intuitive Skin Care 3Health News:Andy Tate, North Star Resource Group Advisor, Named One of Medical Economics' '150 Best Financial Advisors for Doctors' 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 3Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 4Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 5Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 6Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 7Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 8Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 10Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 11Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 12Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 13Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 14Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 15Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 16Health News:Bioniche Reports Fiscal 2009 First Quarter 2Health News:Bioniche Reports Fiscal 2009 First Quarter 3Health News:Bioniche Reports Fiscal 2009 First Quarter 4Health News:Bioniche Reports Fiscal 2009 First Quarter 5Health News:Bioniche Reports Fiscal 2009 First Quarter 6Health News:Bioniche Reports Fiscal 2009 First Quarter 7Health News:Bioniche Reports Fiscal 2009 First Quarter 8Health News:Bioniche Reports Fiscal 2009 First Quarter 9Health News:Bioniche Reports Fiscal 2009 First Quarter 10Health News:Bioniche Reports Fiscal 2009 First Quarter 11Health News:Bioniche Reports Fiscal 2009 First Quarter 12
Glass Whole Blood Tube with K3EDTA...
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EGG or EMG recordings. Surface Electrodes, Skin Preparation and Conductive Cream complete the setup for a EGG study and are essenti...
Medicine Products: